Last reviewed · How we verify
Brenetafusp and chemotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Brenetafusp and chemotherapy (Brenetafusp and chemotherapy) — Immunocore Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Brenetafusp and chemotherapy TARGET | Brenetafusp and chemotherapy | Immunocore Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Brenetafusp and chemotherapy CI watch — RSS
- Brenetafusp and chemotherapy CI watch — Atom
- Brenetafusp and chemotherapy CI watch — JSON
- Brenetafusp and chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Brenetafusp and chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/brenetafusp-and-chemotherapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab